What is DMK Pharmaceuticals 12-1 Month Momentum %?
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-06), DMK Pharmaceuticals's 12-1 Month Momentum % is -99.02%.
The industry rank for DMK Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:
DMKPQ's 12-1 Month Momentum % is ranked worse than 99.37% of 1115
companies
in the Drug Manufacturers industry
Industry Median: -6.53
vs DMKPQ: -99.02
Competitive Comparison of DMK Pharmaceuticals's 12-1 Month Momentum %
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DMK Pharmaceuticals's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
DMK Pharmaceuticals 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of DMK Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DMKPQ has been successfully added to your